Date: 2011-06-02
Type of information: R&D agreement
Compound: Yervoy® (ipilimumab), in combination with Roche’s investigational oral BRAF inhibitor, vemurafenib
Company: BMS (USA) Roche (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: combination of an oral BRAF inhibitor with a monoclonal antibody that blocks the cytotoxic T- lymphocyte antigen-4 (CTLA-4), a negative regulator of T-cell activation
Disease: metastatic melanoma
Details: BMS has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb’s CTLA-4 inhibitor, Yervoy® (ipilimumab), in combination with Roche’s investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma. Under the agreement, the two companies will conduct a Phase I/II study to evaluate the safety and efficacy of the combination. If appropriate, the companies may conduct further development of the combination. This agreement represents an important cross-company collaboration exploring the potential role of this regimen in the treatment of metastatic melanoma.
Financial terms: Financial details were not disclosed.
Latest news:
